Stockholm3® Prostate Cancer Risk Blood Test

Evaluate your risk of clinically significant prostate cancer with high precision. The Stockholm3® blood test combines 5 protein biomarkers, 101 genetic markers, and key clinical data to provide a comprehensive risk score—detecting aggressive cancers early while reducing unnecessary, invasive prostate biopsies by up to 50%.

Stockholm3 evaluates 5 protein markers (including Total PSA, Free PSA, hK2, MSMB, and MIC1), 101 single nucleotide polymorphisms (SNPs / genetic markers), and individual clinical risk factors (age, family history, previous biopsies, and 5-ARI medication use). The test combines this information to give a risk score on the likelihood of clinically significant prostate cancer.

The test will provide clear, interpretable results ranging from Low to High risk. High Risk warrants referral to a urologist for further investigation.

Stockholm3 is equivalent across diverse ethnicities, and has been prospectively validated in more than 90,000 men with results published in more than 30 peer reviewed articles. Publications include the NICE briefing (August 2022) which is helpful in suggesting that Stockholm3 is more effective at predicting risk of prostate cancer than PSA alone.

Key characteristics

• Increased early detection – increased sensitivity.
• Increased specificity reduces over testing, over diagnosis, over treatment and unnecessary biopsies (by 50%).
• Higher accuracy compared to PSA and other prostate cancer risk calculations.
• PSA testing cannot distinguish between aggressive and benign tumours.
• Validated in combination with MRI and in multiple ethnicities.
• Shown to detect clinically significant prostate cancers in PSA levels of 1.5 – 2.9 ng/ml.

Frequently Asked Questions (FAQs)

How is Stockholm3® different from a standard PSA test?

A standard PSA test only measures prostate-specific antigen, which can rise due to non-cancerous conditions like benign prostatic hyperplasia (BPH) or inflammation. Stockholm3® combines 5 protein markers with 101 genetic markers and clinical history, providing significantly higher accuracy and reducing false alarms.

What does my Stockholm3® score mean?

The report provides a numerical risk score (0–100%):

• Normal / Low Risk Score (Less than 11%): Low risk of aggressive cancer; re-testing typically recommended in 2–6 years depending on clinical history.
• Increased Risk Score (11% or more): Indicates increased risk of clinically significant prostate cancer. Further evaluation by a urologist (e.g., multi-parametric MRI) is recommended.